Virpax Pharmaceuticals, Inc., a Delaware-incorporated company trading under the symbol VRPX on The Nasdaq Capital Market, has received a deficiency notice from Nasdaq on October 4, 2024. The notice informed the company that its common stock's closing bid price had been below the $1.00 minimum requirement for the past 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Despite this, the stock will continue to trade on Nasdaq. Virpax Pharmaceuticals has until April 2, 2025, to meet the minimum bid price requirement, with the possibility of a 180-day extension. The company is considering measures to regain compliance, such as a reverse stock split, but there is no guarantee of success. Additionally, on October 5, 2024, CEO Gerald Bruce and CFO Vinay Shah resigned due to disagreements with the Board's policies. The following day, Jatinder Dhaliwal was appointed as the new CEO and Katharyn Field took over Dhaliwal's position on the Board's audit committee.

Virpax Pharmaceuticals, Inc., a Delaware-incorporated company trading under the symbol VRPX on The Nasdaq Capital Market, has received a deficiency notice from Nasdaq on October 4, 2024. The notice informed the company that its common stock's closing bid price had been below the $1.00 minimum requirement for the past 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Despite this, the stock will continue to trade on Nasdaq. Virpax Pharmaceuticals has until April 2, 2025, to meet the minimum bid price requirement, with the possibility of a 180-day extension. The company is considering measures to regain compliance, such as a reverse stock split, but there is no guarantee of success. Additionally, on October 5, 2024, CEO Gerald Bruce and CFO Vinay Shah resigned due to disagreements with the Board's policies. The following day, Jatinder Dhaliwal was appointed as the new CEO and Katharyn Field took over Dhaliwal's position on the Board's audit committee.